Abstract
We investigated the efficacy of 2-week and 4-week pretreatments with 100 mg/day chlormadinone acetate (CMA) to prevent the flare reaction induced by luteinizing-hormone-releasing hormone (LHRH) in patients with metastatic carcinoma of the prostate. CMA lead-in therapy suppressed bone pain and serum levels of luteinizing hormone, testosterone and prostate-specific antigen levels. CMA therapy also suppressed the transient increases in these levels associated with the initiation of therapy. The 4-week regimen appeared to be more effective than the 2-week regimen.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Administration, Oral
-
Aged
-
Aged, 80 and over
-
Carcinoma / blood*
-
Carcinoma / prevention & control
-
Chlormadinone Acetate / therapeutic use*
-
Disease Progression
-
Gonadotropin-Releasing Hormone / adverse effects*
-
Humans
-
Injections, Subcutaneous
-
Luteinizing Hormone / blood*
-
Luteinizing Hormone / drug effects
-
Male
-
Middle Aged
-
Premedication
-
Prostate-Specific Antigen / blood*
-
Prostate-Specific Antigen / drug effects
-
Prostatic Neoplasms / blood*
-
Prostatic Neoplasms / prevention & control
-
Testosterone / blood*
Substances
-
Chlormadinone Acetate
-
Gonadotropin-Releasing Hormone
-
Testosterone
-
Luteinizing Hormone
-
Prostate-Specific Antigen